Balyasny Asset Management
ADCT icon

Balyasny Asset Management’s ADC Therapeutics ADCT Stock Holding History

Balyasny Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$292K Buy
+77,947
New +$307K ﹤0.01% 2568
2024
Q2 		– Sell
-23,765
Closed -$107K – 2514
2024
Q1 		$107K Buy
+23,765
New +$87.7K ﹤0.01% 2489
2022
Q3 		– Sell
-86,100
Closed -$684K – 2808
2022
Q2 		$684K Buy
+86,100
New +$815K ﹤0.01% 1889

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Balyasny Asset Management's ADCT Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in ADC Therapeutics (ADCT) in Q1 2026: 77,947 shares worth $292K. The stake represents ﹤0.01% of the portfolio and ranks #2568 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in ADCT as recently as Q1 2024.

Balyasny Asset Management first reported a position in ADCT in Q2 2022 and has held it in 3 quarters since. The position peaked at $684K in Q2 2022. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Balyasny Asset Management held 77,947 shares of ADC Therapeutics worth $292K as of Q1 2026.
  • ADC Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • ADC Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2568 holding.
  • Balyasny Asset Management first reported a position in ADC Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • Balyasny Asset Management's ADC Therapeutics position peaked at $684K in Q2 2022.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.